AbbVie Inc (ABBV)vsEton Pharmaceuticals Inc (ETON)
ABBV
AbbVie Inc
$227.23
-2.14%
HEALTHCARE · Cap: $391.50B
ETON
Eton Pharmaceuticals Inc
$27.40
-4.46%
HEALTHCARE · Cap: $889.70M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 72161% more annual revenue ($62.82B vs $86.93M). ABBV leads profitability with a 5.8% profit margin vs -1.7%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ETON
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Intrinsic value data unavailable for ETON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 40.4% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Trading at 24.5x book value
ROE of -4.8% — below average capital efficiency
Earnings declined 12.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : ETON
The strongest argument for ETON centers on Revenue Growth. Revenue growth of 40.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : ETON
The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while ETON is a hypergrowth play — different risk/reward profiles.
ETON carries more volatility with a beta of 0.89 — expect wider price swings.
ETON is growing revenue faster at 40.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Eton Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?